Trial Profile
A Phase I, Open Label, Randomized, Two Period, One-Way Two Sequence Crossover Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING111405).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Darunavir; Lopinavir/ritonavir; Ritonavir
- Indications HIV infections
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 20 May 2010 Results have been published in the Journal of Clinical Pharmacology.
- 15 Sep 2009 Results were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
- 18 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.